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Background. Chronic hepatitis C virus (HCV) infection affects 71 million individuals, mostly residing in low- and middle-
income countries (LMICs). Direct-acting antivirals (DAAs) give high rates of sustained virological response (SVR) in high-income 
countries where a restricted range of HCV genotypes/subtypes circulate.
Methods. We studied United Kingdom–resident patients born in Africa to examine DAA effectiveness in LMICs where there is 
far greater breadth of HCV genotypes/subtypes. Viral genome sequences were determined from 233 patients.
Results. Full-length viral genomic sequences for 26 known subtypes and 5 previously unidentified isolates covering 5 HCV 
genotypes were determined. From 149 patients who received DAA treatment/retreatment, the overall SVR was 93%. Treatment 
failure was associated primarily with 2 subtypes, gt1l and gt4r, using sofosbuvir/ledipasvir. These subtypes contain natural resistance-
associated variants that likely contribute to poor efficacy with this drug combination. Treatment failure was also significantly asso-
ciated with hepatocellular carcinoma.
Conclusions. DAA combinations give high SVR rates despite the high HCV diversity across the African continent except for 
subtypes gt1l and gt4r, which respond poorly to sofosbuvir/ledipasvir. These subtypes are widely distributed across Western, Central, 
and Eastern Africa. Thus, in circumstances where accurate genotyping is absent, ledipasvir and its generic compounds should not be 
considered as a recommended treatment option.
Keywords.  HCV; direct-acting antiviral; DAA; treatment outcomes; Africa; viral genotypes/subtypes.
Direct-acting antivirals (DAAs) capable of clearing chronic 
hepatitis C virus (HCV) infection from 90%–95% of treated in-
dividuals are a cornerstone of the World Health Organization 
(WHO) strategy to eliminate viral hepatitis as a public health 
concern by 2030 [1]. Consequently, many high-income coun-
tries (HICs) have implemented action plans for controlling 
infection and transmission to achieve HCV eradication. By con-
trast, low- and middle-income countries (LMICs) face obstacles 
and challenges limiting their ability to implement similar strat-
egies [2]. Moreover, clinical trials and data on DAA efficacy are 
almost exclusively derived from studies in HICs where circu-
lating HCV genotypes (gt)/subtypes are more restricted than 
those in LMICs [3–6]. In particular, most subtypes of HCV 
gt4, gt5, and gt6 have been largely neglected, yet they represent 
about 15% of chronic HCV infections [7].
We recently reported a substantial gap in our knowledge 
of HCV genomic sequences circulating in LMICs across 
large geographic areas [8]. In addition, we and others have 
identified HCV gt1 and gt4 subtypes in infected patients of 
African origin that do not respond to DAA therapy as well 
as subtypes typically transmitted in HICs; treatment failure 
using a sofosbuvir (SOF)/ledipasvir (LDV) combination 
has been particularly evident with HCV subtypes gt1l [9, 
10] and gt4r [10–14]. Reduced DAA efficacy for these sub-
types is frequently related to polymorphisms in DAA target 
proteins (herein defined as resistance-associated variants 
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[RAVs]), which can give inherent resistance to certain DAA 
combinations.
In this study, we address the issue of treatment outcomes 
in response to DAA therapy in HCV-infected individuals 
originating from Africa but residing in the United Kingdom 
(UK). We also aimed to increase the number of available com-
plete HCV genomic sequences derived from African patients, 
as there is a lack of such genetic data in public databases.
METHODS
Study Design and Patients
HCV-infected patients were enrolled into the HCV Research 
UK cohort at clinical sites in the UK [15]. All patients whose 
country of birth was in Africa were included in this study. 
Further details of the HCV Research UK clinical database are 
given in the Supplementary Methods. The study conforms to 
the ethical guidelines of the 1975 Declaration of Helsinki as re-
flected in a priori approval by the institution’s human research 
committee. Ethics approval for HCV Research UK was given 
by National Research Ethics Service (NRES)  Committee East 
Midlands–Derby 1 (Research Ethics Committee reference 11/
EM/0314).
Next-Generation Sequencing by Metagenomics and Target Enrichment
The next-generation sequencing (NGS) methods for deter-
mining HCV viral sequences by metagenomics and target en-
richment have been published previously [16] and are described 
in the Supplementary Methods.
HCV Sequence and Variant Analysis
Next-generation sequencing data quality was assessed using 
FastQC (http://www.bioinformatics.babraham.ac.uk/pro-
jects/fastqc/), and low-quality bases (Phred score <30 or read 
length  <50 nucleotides) were trimmed using Trim Galore! 
script (https://www.bioinformatics.babraham.ac.uk/projects/
trim_galore/). Cleaned reads were submitted for de novo as-
sembly using SPAdes [17]. Where de novo assembly failed to 
generate a full-length contig, reads were mapped to the closest 
reference genome. Reference genomes were selected by a kmer-
based approach using unique kmers from all HCV genotypes. 
Reads were mapped to the reference genome (or to de novo 
contigs) using Tanoti read mapper (https://bioinformatics.
cvr.ac.uk/software/tanoti/). Any minor variants associated 
with DAA resistance were identified using the GLUE software 
package samReporter with default settings [18, 19].
Statistical Analysis
Statistical analyses were performed using Stata version 10 soft-
ware. Continuous variables were reported as median (and in-
terquartile range) and analyzed by the Mann–Whitney U test 
for univariate analysis. Categorical univariate analysis was per-
formed using Fisher exact test. Multivariate analysis was carried 
out using logistic regression. Variables with a P value of <.1 in 
univariate analysis were included in multivariate analysis.
RESULTS
Demographics of Subjects Originating From Africa in the Cohort
Within the HCV Research UK cohort [15], 319 patients were 
born in 32 countries across Africa. Analysis of this African 
group revealed that 66.5% were male (Table 1) with an age 
range of 24–88 years, averaging 59 years. The most frequently 
cited probable sources of infection were “born abroad” (40%) 
and “blood/blood products” (17%) (Table 1). “Born abroad” 
was included as it was significantly associated as a risk factor 
for infection in a previous study [20]. Only 10% of individuals 
probably acquired infection through injection drug use, con-
siderably lower than that for white UK nationals from the HCV 
Research UK cohort (n = 5360/8419 [64%]). Moreover, 44 cases 
were cited as “other” (14% of the cohort) as a probable source 
of infection; within this category, there was a range of possible 
sources of infection, but none were reported as having acquired 
infection in the UK (Supplementary Table 1). Indeed, for 11 in-
dividuals, country of birth was recorded specifically as the likely 
location for acquiring infection (Table 1 and Supplementary 
Table 1).
A high proportion of the African cohort had cirrhosis 
(n  =  131 [41%]) and, within this group, decompensated dis-
ease was found in 42 individuals (32%). In addition, 25 cases 
(19%) were diagnosed with hepatocellular carcinoma (HCC) 
Table 1. Demographics of Hepatitis C Virus–Infected Individuals 
Originating From Africa (N = 319)
Characteristic No. (%)
Sex   
 Male 212 (66.5)
 Female 105 (33)
 Not known 2 (<1)
Cirrhosis (n = 131)a   
 No decompensation 53 (40.5)
 Decompensated 42 (32)
 HCC 25 (19)
 Decompensated + HCC 11 (8.5)
Probable source of infection (N = 319)   
 Born abroad 127 (40)
 Blood/blood product 54b (17)
 Injection drug use 33 (10)
 Known HCV-positive partner 6 (2)
 Perinatal exposure 1 (<0.1)
 Other 44 (14)
 No known risk factor 29 (9)
 Data incomplete 7 (2)
 No data entry 18 (5.5)
Abbreviations: HCC, hepatocellular carcinoma; HCV, hepatitis C virus.
aStratification of HCV-infected cases with cirrhosis by disease type.
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(Table 1). The percentage of UK-born individuals of white eth-
nicity in the HCV Research UK database with cirrhosis was 
37% (n = 3141/8419). Within this group, the percentage with 
more severe liver disease was considerably less (n = 1203/3141 
[38%]; Supplementary Table 2) compared to the African group 
(n = 78/131 [59.5%]; Table 1).
Identification of HCV Genotypes and Subtypes by Unbiased NGS and 
Target Enrichment
Using a NGS target enrichment approach (described in the 
Supplementary Methods) [16], we generated sequence data 
covering the entire HCV coding region for samples from 233 
individuals (Supplementary Table 3); viral sequence data were 
determined from another 14 samples collected from patients 
after they underwent unsuccessful DAA therapy. Samples that 
did not yield viral sequence data were mostly obtained either 
during or after antiviral therapy (64/86 [75%]), at which point 
either very low or undetectable viral loads would be evident in 
circulating blood.
Using maximum likelihood phylogenetic analysis, we de-
tected 7 gt1 subtypes (and 4 gt1 unassigned isolates), 3 gt2 
subtypes (and 1 gt2 unassigned isolate), 2 gt3 subtypes, 13 gt4 
subtypes, and 2 gt5a sequences; unassigned isolates differed 
from classified HCV subtypes by at least 15% at the nucleotide 
level [21]. Compared to publicly available data, our analysis 
considerably increases the genomic information for 8 subtypes 
(gt1g, gt1l, gt3h, gt4a, gt4c, gt4k, gt4n, and gt4r). The distribu-
tion and occurrence of the HCV genotypes and subtypes iden-
tified in each individual and their country of origin are shown 



















Egypt n = 62
gt1a (8); gt1b (2); gt1g (4); gt3a(2);
gt4a (35); gt4d (3); gt4m (3); gt4n (3);
gt4o (2).
Somalia n = 29
gt1a (5); gt1b (4); gt1g (1); gt3h (5)
gt4m (1); gt4m (1); gt4r (11); gt4v (2).
DR Congo n = 20
gt4a (1); gt4b (1); gt4c (2); gt4f  (2)
gt4g (1); gt4k (6); gt4n (1); gt4r (6).
Nigeria n = 31
gt1a (8); gt1b (3); gt1c (2); gt1l (6);
gt1 unassigned (3); gt4a (1);
gt4c (1); gt4k (1); gt4o (1); 
gt4r (1); gt4t (1); gt4v (3)
South Africa n = 9
gt1a (5); gt1b (1); gt2b (1);













Figure 1. A, Distribution of hepatitis C virus (HCV) genotypes from individuals originating from Northern, Western, Central, Eastern, and Southern Africa. B, Numbers of 
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the geographical locations of all confirmed subtypes for HCV 
gt1–gt4 available in the published literature [21–25], there were 
only 7 subtypes previously found in Africa that were absent in 
our sequencing dataset (Supplementary Table 4).
The most highly represented countries in each geographic 
African region for sequence data were Egypt (n = 62; Northern 
Africa), Nigeria (n = 31; Western Africa), Democratic Republic 
of the Congo (DRC)/Republic of Congo (n  =  20; Central 
Africa), Somalia (n  =  29; Eastern Africa), and South Africa 
(n  =  9; Southern Africa) (Figure 1A and 1B). HCV subtypes 
gt1a and gt1b were ubiquitous in patients born across Africa, 
with either subtype found in individuals from 18 of 27 countries 
(67%). Genotype 4a was the most common subtype in Egyptian 
individuals, as previously reported [26, 27]. Aside from gt1a, 
gt1b, and gt4a, the most frequently detected subtypes were 
gt3a and gt4r, which were found in individuals from 9 of 27 
and 7 of 27 countries, respectively. Genotype 4r was present 
in patients originating from Western Africa (Nigeria), Central 
Africa (Central African Republic and DRC/Republic of Congo), 
and Eastern Africa (Burundi, Eritrea, Ethiopia, and Somalia) 
(Figure 1A and 1B). Strikingly, 38% (11/29) of sequences from 
Somalian patients were gt4r (Figure 1B). Therefore, gt4r is likely 
to be distributed across large areas of Africa and, assuming that 
most individuals were infected in their originating country, 
may dominate in certain countries. Genotype 3h was also de-
tected in patients from Somalia and Zimbabwe and hence may 
be the most common gt3 subtype circulating in certain African 
countries. Indeed, gt3h was the second most prevalent subtype 
in Somalian individuals after gt4r. In addition, our sequence 
studies identified 5 unassigned strains for gt1 and gt2, which 
were detected in patients from Nigeria (n  =  3), Cameroon 
(n = 1), and Ghana (n = 1) (Supplementary Table 3).
We compared the genotypes/subtypes identified by NGS 
analysis with those recorded by the clinical site that used com-
mercial kits (such as the INNO-LiPA test [Innogenetics]). We 
obtained genotype and subtype data for both commercial assays 
and NGS for 133 and 60 samples, respectively (genotype and 
subtype). HCV genotype was identical in 124 samples (93%), 
but the percentage of concordant HCV subtypes was much 
lower (n = 41/60 samples [68%]). The majority of mismatches 
corresponded to subtypes that are not typically identified or dif-
ferentiated in commercial kits (data not shown).
Outcomes of DAA Therapy
We evaluated treatment outcomes for all DAA drug combin-
ations used to treat the cohort, yielding data on 149 patients. 
This group included 12 patients who had received prior DAA 
therapy on 1 (n = 11) or 2 (n = 1) occasions. Hence, there was a 
total of 162 treatment episodes recorded (Table 2). Two patients 
were lost to follow-up or died before treatment outcome was 
known but were included in the overall analysis.
From univariate analysis, presence of HCC (P = .006) was sig-
nificantly associated with DAA failure; a higher failure rate was 
noted also for those with decompensated liver disease (P = .061; 
Supplementary Table 5). No other demographic or clinical char-
acteristics, including HIV infection, were associated with failed 
response to DAA therapy. From combining all types of therapy 
(both interferon [IFN] and DAA based), treatment-naive pa-
tients were significantly more likely to respond compared with 
treatment-experienced individuals (Supplementary Table 5). 
Stratifying the various treatment regimens according to either 
IFN or DAA targeted at HCV proteins (NS3, NS5A, and NS5B) 
revealed that prior exposure to antivirals against NS5A and 
NS5B was significantly associated with subsequent treatment 
failure (Supplementary Table 5).
To identify the basis of this finding, we examined the viral 
sequence data for the group that received DAA therapy. In total, 
viral sequences were available for 131 patients who had received 
144 treatment episodes. The most striking observation from 
analyzing the different DAA combinations for these patients 
Table 2. Direct-Acting Antiviral–Only Regimens and Outcomes for Individuals Originating From Africa
DAA Regimen Total
Treatment Regimen Outcomes (n = 162)
SVR, No. (%) Responder-Relapser Nonresponder Lost to Follow-up Died Before Outcome Known
All 162 136 (84) 21 3 1 1
OBV/PTV/RTV 15 14 (93) 1 0 0 0
OBV/PTV/RTV/DSV 24 24 (100) 0 0 0 0
GLE/PIB 7 6 (86) 0 1 0 0
SOF 4 3 (75) 1 0 0 0
SOF/LDV 71 55 (77) 14 1 0 1
SOF/DCV 14 12 (86) 2 0 0 0
SOF/DCV or LDV 3 3 (100) 0 0 0 0
SOF/VEL 8 6 (75) 1 1 0 0
SOF/VEL/VOX 4 3 (75) 1 0 0 0
GRZ/ELB 12 10 (83) 1 0 1 0
Abbreviations: DAA, direct-acting antiviral; DCV, daclatasvir; DSV, dasabuvir; GLE, glecaprevir; GRZ, grazoprevir; LDV, ledipasvir; OBV, ombitasvir; PIB, pibrentasvir; PTV, paritaprevir; RTV, 
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was low SVR rates for gt1l and gt4r with NS5A/NS5B antiviral 
combinations (0% and 44%, respectively; Table 3). Statistical 
analysis of both HCV subtypes combined showed that a low 
SVR was highly significant in both univariate and multivariate 
analysis compared to other subtypes (Supplementary Table 5). 
By comparison, high SVR rates were achieved for other sub-
types that are common across Africa but found far less fre-
quently in HCV-infected populations in other continents.
Virological Characteristics of Responder-Relapsers/Nonresponders to 
DAA-Based Therapy and Retreatment Outcomes
In terms of virological outcomes (ie, excluding patients either 
lost to follow-up or who died before outcome was known), 
there were 24 treatment episodes with DAA that led to treat-
ment failure (Table 2) in 19 patients. Final records for these pa-
tients showed that 9 were successfully retreated. Four patients 
who were retreated did not achieve SVR and, therefore, 10 pa-
tients remained viremic (Table 4). Five patients were retreated 
with the same drug combination and only 2 (both infected 
with gt3a) achieved SVR. The other 3 patients were infected 
with either gt1l (n = 2) or gt4r (n = 1). Six of 7 patients who 
received retreatment with more potent DAA combinations, ei-
ther glecaprevir (GLE)/ pibrentasvir (PIB) or SOF/velpatasvir 
(VEL)/voxilaprevir (VOX), achieved SVR; the 1 retreatment 
failure in this category was infected with gt4r and received SOF/
VEL/VOX (Table 4).
Sequences in NS5A for Subtypes gt1l and gt4r Potentially Associated With 
Lower Response to DAA Therapy
Given the frequency of gt1l and gt4r treatment failure, we exam-
ined all individuals in the cohort infected with these HCV sub-
types for both their viral sequences and outcomes from antiviral 
therapy. Seven patients were infected with gt1l (Supplementary 
Table 4), 6 of whom received DAA therapy (Table 5). Twenty-
six patients were infected with gt4r (Supplementary Table 4), 12 
of whom received at least 1 episode of DAA therapy (Table 5). 
Combining the data for gt1l and gt4r indicated that there were 
13 instances of DAA treatment failure, 10 of which resulted from 
SOF/LDV treatment; the remaining treatment failures arose 
from use of SOF/daclatasvir (DCV) (n = 2) for a gt1l-infected 
individual and SOF/VEL/VOX for retreatment in a gt4r infec-
tion (Table 4). Previously, we have shown that sequences from 
these subtypes can share a common motif in NS5A, M28R30M31, 
that could give resistance to NS5A inhibitors and thereby re-
duce effectiveness of DAA therapy [10]. From examining the 
NS5A coding region for all gt1l and gt4r viral sequences in the 
cohort, we found that gt1l had 2 patterns at positions 28, 30, 
and 31; methionine was invariant at positions 28 and 31, while 
position 30 encoded either arginine or glutamine (Table 5). The 
same positions in gt4r had more complex amino acid combin-
ations with 6 distinct patterns of residues identified in the 11 
patients who received DAA treatment (Table 5). Position 30 en-
coded an arginine residue that was invariant, while position 31 
encoded predominantly leucine with methionine present at a 
lower frequency. The highest variability was observed at posi-
tion 28 with methionine found at highest frequency, but 4 other 
amino acids were also encoded at this position (Table 5).
DISCUSSION
Our study had 2 major objectives; first, to analyze DAA treat-
ment outcomes for individuals originating from countries 
across Africa, and second, to determine the HCV sequences cir-
culating in the cohort. Given the sparsity of viral sequences at 
RAV positions and real-world outcomes of DAA therapy from 
African individuals, our study addresses a critical gap in such 
information from LMICs [8].
The cohort totaled 319 individuals, originating from 32 
African countries. This gives a broad geographical spread with 
larger groups coming from Egypt (Northern Africa), Nigeria 
(Western Africa), DRC/Republic of Congo (Central Africa), 
Somalia (Eastern Africa), and South Africa (Southern Africa). 
For most individuals, HCV infection was likely acquired in 
their country of origin given their more advanced stage of 
liver disease (Table 1 and Supplementary Table 2) and the 




All DAA Regimens NS3/NS5A DAA Regimens NS5A/NS5B DAA Regimens NS3/NS5A/NS5B DAA Regimens
All 119/144 (83) 27/31 (87) 67/87 (77) 25/26 (96)
gt1a 23/26 (88) 3/5 (60) 16/17 (94) 4/4 (100)
gt1b 16/17 (94) 3/3 (100) 8/9 (89) 5/5 (100)
gt1l 3/10 (30) 1/1 (100) 0/7 (0) 2/2 (100)
gt3a 7/9 (90) 1/1 (100) 6/8 (75) 0
gt4a 25/27 (93) 10/11 (91) 12/13 (92) 3/3 (100)
gt4d 4/4 (100) 0 3/3 (100) 1/1 (100)
gt4r 9/15 (60) 2/2 (100) 4/9 (44) 3/4 (75)
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diversity of genotypes and subtypes represented in our anal-
ysis (Supplementary Tables 3, 4, and 6), as reported previously 
for African individuals [22–25, 28]. In addition, some indi-
viduals reported likely transmission in their country of origin 
(Supplementary Table 1). We cannot exclude the possibility that 
a proportion of infections occurred in the UK or in countries 
from which individuals did not originate. In the UK, HCV is 
predominantly found in people who inject drugs (PWID), and 
the genotypes observed are almost exclusively gt1 (53%) and gt3 
(41%; Supplementary Table 6). By contrast, African individuals 
had much lower occurrence of gt3 infection (8%) but far higher 
prevalence of gt4 infection (47% compared to 0.5% in the UK 
PWID population; Supplementary Table 6). Moreover, the sub-
types identified in the UK PWID population are typically gt1a, 
gt1b, and gt3a (data not shown), but there is greater diversity 
of gt1 subtypes in the African group (Supplementary Tables 3 
and 4) and there were no cases of gt3h in the UK PWID co-
hort. We did attempt to distinguish gt1a, gt1b, and gt3a strains 
in African individuals compared to UK-based infections, but 
phylogenetic analysis did not discriminate between possible 
UK and African strains (data not shown). Thus, it is highly 
probable that for the African group, HCV infection occurred 
in their country of origin. Far larger studies would be required 
to determine whether the higher prevalence of liver disease was 
associated with any virological factors given the infrequency of 
many of the subtypes outside Africa.
Almost half of the cohort was treated with 9 different DAA 
regimens including NS3 protease + NS5A inhibitors, NS5A + 
NS5B inhibitors, and drug combinations against all 3 viral tar-
gets. The most frequently prescribed DAA therapies were SOF-
based regimens (104/162 [64%]). SOF was occasionally used 
as mono-DAA therapy with ribavirin (RBV) but was mostly 
prescribed in dual combination with NS5A inhibitors with or 
without RBV (LDV, VEL, or DCV) or triple combination (VEL/
VOX) (Table 2). The overall SVR for SOF-based treatment was 
79% (82/104). This relatively low SVR rate was primarily a con-
sequence of relapse with SOF/LDV in gt1l- and gt4r-infected 
patients (Table 2). These findings confirm previous reports from 
ourselves and others on the lower SVR rates achieved with SOF/
LDV therapy for both of these subtypes [9–14]. By contrast, 8 
of 9 patients (89%) infected with either gt1l or gt4r achieved 
SVR following treatment with either NS3/NS5A combinations 
or triple SOF/VEL/VOX treatment.
Aside from gt1l and gt4r, the SVR for other gt1 and gt4 
subtypes was 97%. This includes gt4d, another unusual sub-
type associated with treatment failure with ombitasvir (OBV)/
paritaprevir (PTV)/ritonavir (RTV) in a clinical trial [29]. There 
were 4 gt4d-infected patients in our study, all of whom achieved 
SVR with OBV/PTV/RTV (n  =  1) and SOF-based therapy 
(n = 3). Thus, it is likely that there are few gt1 and gt4 subtypes, 
other than gt1l and gt4r, circulating in Africa that would not 
give high SVR rates for the various DAA therapies. Nonetheless, 
exceptions could arise such as the unassigned gt1 strain from a 
Nigerian patient who had a T28 + S30 + N93 amino acid com-
bination in NS5A and was a responder-relapser to grazoprevir/
elbasvir treatment (patient 2 in Table 4). Moreover, the gt1a-
infected case, who was classified as a nonresponder to GLE/PIB, 
had a natural M31 RAV in NS5A that appears infrequently in 
gt1a sequences but could arise more frequently in certain LMIC 
populations that have not been extensively analyzed. Thus, con-
tinued surveys of viral sequences in Africa and outcomes from 
therapy would be beneficial.
Thirteen patients in our cohort who were not success-
fully cured by initial DAA therapy received retreatment, with 
9 achieving SVR. Aside from 1 individual who relapsed on 
retreatment, the more potent DAA combinations containing 
GLE/PIB and SOF/VEL/VOX achieved cure in 6 patients. SOF/
VEL/VOX retreatment was unsuccessful in 1 individual with 
gt4r (Table 4) who had received previous unsuccessful SOF/
LDV therapy. The reason for retreatment failure with SOF/VEL/
Table 5. NS5A Sequences at Sites Associated With Direct-Acting Antiviral (DAA) Resistance and Outcomes of DAA Treatment Regimens for Individuals 
Infected With Genotype 1l or Genotype 4r
NS5A Position
Frequency
NS3/NS5A Rx NS5A/NS5B Rx NS3/NS5A/NS5B Rx
28 30 31 NRx NSVR NRx NSVR NRx NSVR
gt1l n = 6 1 1 7 0 2 2
M Q M n = 3 0 0 3 0 1 1
M R M n = 3 1 1 4 0 1 1
gt4r n = 12 2 2 9 4 4 3
M R L n = 6 1 1 4 2 2 2
M R M n = 1 0 0 2 0 0 0
V R L n = 2 0 0 2 1 1 0
F R L n = 1 0 0 1 1 0 0
I R L n = 1 0 0 0 0 1 1
T R L n = 1 1 1 0 0 0 0
Underlined amino acids indicate possible resistance-associated variants.
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VOX is not known since there were no serial samples available 
following SOF/LDV treatment. In addition, the patient did not 
have underlying severe liver disease. We also did not find any 
potential resistance-associated substitutions (RASs) in the NS3 
protein that could explain lack of efficacy for VOX. It is pos-
sible that initial SOF treatment could have led to emergence of 
an S282T RAS in NS5B, which would yield high levels of re-
sistance. From previous reports, S282T appears to emerge at 
higher frequency with gt4r than other HCV genotypes and 
subtypes [10, 13]. This RAS did emerge transiently in 1 patient 
in our study (patient 9 in Table 4) following initial SOF/LDV 
treatment. We also found a V321I variant [12] in the NS5B 
sequences of 6 gt4r-infected patients who received SOF treat-
ment; 3 patients achieved SVR whereas the remainder relapsed 
from therapy. Notably, in the French study that documented 
successful retreatment outcomes in 7 patients infected with 
gt4r, again GLE/PIB and SOF/VEL/VOX were used in most 
retreatment regimens [13]. Overall, studies from our group and 
others agree that SOF/LDV therapy is suboptimal and should 
not be recommended in regions with potentially significant 
prevalence of gt1l and gt4r infection. This recommendation is 
reinforced by a recent report using subgenomic replicons con-
taining gt1l and gt4r NS5A sequences, which shows that vari-
ants at positions 30 and 31 identified here increase resistance to 
LDV [30]. It is worth noting that African [14], UK [9, 10], and 
French studies [11–13] have now highlighted difficulties with 
treating patients of African origin infected with these subtypes 
using SOF/LDV therapy. Therefore, treating this patient group 
with a SOF/LDV combination in high-income settings should 
be avoided unless robust HCV genotype/subtype assays are 
available. In resource-limited settings where there is consider-
able diversity of HCV genotypes and subtypes that could include 
gt1l and gt4r, more potent pangenotypic DAA combinations 
should prove effective as either initial or rescue therapy, thereby 
obviating the need for sophisticated assays for viral genotyping 
and subtyping. During the review of this manuscript, the most 
recent European Association for the Study of the Liver (EASL) 
guidelines excluded SOF/LDV as recommended therapy, but do 
highlight the need for additional treatment outcome data for 
unusual HCV subtypes such as gt1l and gt4r with more potent 
DAA combinations [31].
In conclusion, our study describes HCV subtypes and viral 
sequences circulating in countries for which there are very 
limited data, and complements our recent report describing 
gt4 subtypes in Uganda and DRC as well as novel gt7 strains 
[22]. Crucially, we show that gt4r is not a “rare” subtype across 
large geographical regions in Africa. Indeed, excluding Egypt 
where gt4a dominates [26, 32], gt4r is the most prevalent gt4 
subtype in our study and therefore may be highly prevalent in 
certain African countries. Moreover, the extent of gt1l infec-
tion in Nigeria and other unassigned gt1 strains has not been 
fully evaluated. As highlighted in EASL guidelines, it would 
be prudent to continue to record outcome data to determine 
the optimum regimens for use in regions where such subtypes 
circulate.
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